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Abstract. Eight novel diamidino 3,4-ethylenedioxythiophene-2,5-dicarboxanilides (5a–h), obtained by 
condensation reaction of 3,4-ethylenedioxythiophene-2,5-dicarbonyl chloride and corresponding 3- or 4-
aminobenzamidines, were evaluated for interactions with double-stranded DNA and RNA, and their cyto-
toxicity was assayed against the panel of human cancer cell lines. All compounds preferentially bind into 
the minor groove of DNA and had higher affinity for DNA than for RNA. Compounds 5a–h showed a 
moderate antiproliferative effect toward the panel of seven carcinoma cells line, whereby the highest in-
hibitory potential was displayed by compound 5a with unsubstituted amidino moieties in para position. 
(doi: 10.5562/cca2141)  
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INTRODUCTION 
Cancer is one of the leading causes of death in the 
world. The toll taken in human cost and health care 
economy is enormous. Deaths from cancer worldwide 
are projected to continue rising from 7.6 million in 2008 
to an estimated 13.1 million in 2030.1 The majority of 
the currently available drugs have well established 
shortcomings, such as poor efficiency, non-selectivity, 
and high toxicity in non-cancerous cells.2 Considering 
this, the development of new anticancer agents that 
selectively act on the target, with high potency and less 
toxicity, is urgently needed. 
Recent developments in genomic and molecular 
biology have provided new information about the genes 
from cancer cells. Despite this new information, DNA-
targeted chemotherapy of cancer is still largely based on 
the application of drugs that have been in use for some 
time.3–5 Among different structures, notable attention 
has been given to rational design, synthesis and charac-
terisation of the structure-activity relationship of diaryl-
amidines, small molecules that bind through noncova-
lent interaction to the minor groove of B-DNA.6–8 
Diarylamidines have a wide range of potential 
therapeutic applications, such as ACIS inhibitors,9 
antiparasitic,10,11 antifungal,12 antibacterial,13,14 antivi-
ral15 and anticancer agents.4,6,16,17 Until now, 
pentamidine, 1,5-bis(4-amidinophenoxy)pentane, is the 
only one of this class with significant human clinical 
use. The development of pentamidine as a therapeutic 
drug is limited due to its known toxic side effects as a 
consequence of parent drug metabolism.18 Unfortunate-
ly, metabolic breakup of the parent molecule may be a 
problem encountered with many of direct pentamidine 
analogues, especially those containing an ether bond in 
the bridge between the cationic moieties.12 
It is well established that varying the central link-
er, substitutive group or substituent position can create a 
significant difference in the space configuration and 
distribution of electron density within the molecule, and 
thus influence the DNA-binding mode.19,20 This stimu-
late us to design, synthesize and test the new 
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pentamidine analogues with a robust 3,4-
ethylenedioxythiophene (EDOT) linker instead of an 
unstable alkyl chain18 or unstable benzo[c]thiophene 
ring.21 Diarylamidine derivatives of EDOT previously 
synthesized in our laboratory (Figure 1) have shown 
significant antitumor activity.22,23 The obtained results 
show that small changes in molecular structure have 
profound effects on DNA recognition and biological 
activity. It was found that tested compounds prefer 
binding into minor groove of ds-DNA over ds-RNA. 
To obtain further information on the DNA binding 
modes of this type of compounds, we have synthesized 
new derivatives of EDOT, namely, 2,5-bis[(amidino-
phenyl)carboxamide]-3,4-ethylenedioxythiophene 5a–h 
with the terminal amidine group in para- or meta- posi-
tion. Two types of structural modifications were tested, 
the nature of the central linker and the position of 
amidine groups and thereby the influence of electron 
density and geometric shape on interactions with DNA 
and biological activity of newly synthesized com-
pounds. A few series of similar compounds, in which 
two phenylamidines are linked by different bridges 
containing carboxamide moieties, their DNA/RNA 
binding affinities and broad spectra of biological activi-
ty have been described earlier.7,24–26 
To test the flexibility and structural characteristics 
of the linker, comprising a poorly electron-donating 
amide moiety in addition to thiophene with an electron 
releasing cyclic ether, we prepared N-alkyl or N-phenyl 
derivatives of 3,4-ethylenedioxythiophene-2,5-dicarbox-
amide and studied the stability of prepared compounds, 
amide bond isomerisation and twisting of the dioxane 
ring by experimental methods (tandem mass spectrome-
try, X-ray structure analysis) and theoretical DFT calcu-
lations.27,28 Mass spectrometry was used as the most 
widespread method for detection of metabolites and 
fragments produced by degradation of parent molecules, 
because early identification of potential metabolic liabil-
ities provides a better perspective in the design of new 
drug candidates. 
 
EXPERIMENTAL 
Compounds 
The aminobenzamidine compounds 4a, 4e, 4f and 4g 
are commercially available, and synthesis of compounds 
2 and 4b were published earlier.23,29 The synthesis and 
physical properties of the others compounds are given 
as follows. 
Solvents were distilled from appropriate drying 
agents shortly before use. TLC was carried out on DC-
plastikfolien Kieselgel 60 F254, Merck. Melting points 
were determined on a Büchi 510 melting point appa-
ratus and were uncorrected. IR spectra [νmax / cm–1] were 
obtained on a Bruker Vertex 70 spectrophotometer.  
The 1H and 13C NMR spectra were recorded on a  
Bruker Avance 300 MHz spectrometer. Chemical shifts 
(δ / ppm) were referred to TMS. Mass spectra were 
recorded on a Waters Micromass Q-ToF micro. Ele-
mental analyses were performed by the Applied Labo- 
ratory Research Department at INA d.d., Research and 
Development Sector, Central Analytical Laboratory. 
 
General Method for the Synthesis of 3- or 4-Aminobenz- 
amidines 
A solution of 3- or 4-aminobenzonitrile (3a or 3b) (9.13 
g, 77.4 mmol) in anhydrous CH3OH (230 mL) was 
cooled in an ice bath and saturated with dry HCl gas. 
The suspension was stirred at room temperature until IR 
spectra indicated the absence of the cyano peak (8 
days). Anhydrous diethyl ether was added to the sus-
pension and the solid was collected by filtration, washed 
with anhydrous diethyl ether and dried under reduced 
pressure over KOH to yield 13.77 g (95.4 %) of the 
corresponding imidate ester hydrochloride. The result-
ing salt was used in the next step without additional 
purification. 
The crude imidate ester hydrochloride (2.98 g, 
16.0 mmol) was suspended in anhydrous methanol (50 
mL) and the corresponding amine was added. The sus-
pension was stirred at room temperature for 4 days 
under nitrogen atmosphere. The solvent was removed 
under reduced pressure and the residue was recrystal-
lized from ethanol-diethyl ether.  
 
4-Amino-N-isobutylbenzamidine Hydrochloride (4c) 
Amine: isobutylamine (2.58 g, 35.28 mmol); yield 3.12 
g (86.2 %) of white powder; m.p. > 250 °C; IR 
(νmax / cm–1): 3143, 1598, 1500, 1313, 1050, 665, 497; 
1H NMR (DMSO-d6) δ /ppm: 9.31 (s, 1H, NH), 9.00 (s, 
1H, NH), 8.65 (s, 1H, NH), 7.53 (d, 2H, J = 8.64 Hz, 
 
Figure 1. 
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ArH), 6.64 (d, 2H, J = 8.70 Hz, ArH), 6.17 (s, 2H, 
NH2), 3.20 (t, 2H, J = 6.52 Hz, CH2) 1.98 (m, 1H, J = 
6.77 Hz, CH), 0.93 (d, 6H, J = 6.67 Hz, CH3);  
4-Amino-N-cyclopentylbenzamidine Hydrochloride (4d) 
Amine: cyclopentylamine (7.24 mL, 6.16 g, 73.12 
mmol); yield 3.79 g (98.9 %) of white powder; m.p. > 
250 °C; IR (νmax / cm–1): 3570, 3194, 1589, 1515, 1326, 
1095, 834, 675; 1H NMR (DMSO-d6) δ /ppm: 7.42 (d, 
2H, J = 8.58 Hz, ArH), 6.55 (d, 2H, J = 8.61 Hz, ArH), 
5.59 (s, 2H, NH2), 3.97 (q, 1H, J = 6.51 Hz, CH) 1.90 
(m, 2H, CH2), 1.68 (br s, 2H, CH2), 1.51 (m, 4H, CH2);  
2-(3-Aminophenyl)-4,5-dihydro-1H-imidazol Hydrochlo- 
ride (4h) 
Amine: 1,2-ethylenediamine (7.0 mL, 6.3 g, 10.48 
mmol); yield 2.01 g (53.6 %) of white powder; m.p. > 
250 °C; IR (νmax / cm–1): 3215, 1630, 1594, 1576, 1493, 
1374, 1290, 864, 785, 781, 713, 698, 543, 528; 1H NMR 
(DMSO-d6) δ /ppm: 9,89 (s, 2H, NH), 7.24 (t, 1H, J = 
7.79 Hz, ArH), 7.04 (td, 1H, J1 = 7.60 Hz, J2 = 0.83 Hz, 
ArH), 6.99 (t, 1H, J = 1.83 Hz, ArH), 6.91 (ddd, 1H, J1 
= 8.15 Hz, J2 = 2.18 Hz, J3 = 0.84 Hz, ArH), 5.44 (s, 
2H, NH2), 3.96 (s, 4H, –CH2CH2–).  
2,5-Bis[N-(4-amidinophenylcarboxamide)]-3,4-ethylene- 
dioxythiophene Dihydrochloride (5a) 
A suspension of 3,4-ethylenedioxythiophene-2,5-dicarbo-
nyl chloride (2) (2.65 g, 9.9 mmol) and compound 4a 
(3.63 g, 17.5 mmol) in dry chloroform (150 mL) was 
stirred under reflux for 3 days under nitrogen atmos-
phere. The solvent was removed under reduce pressure, 
and the residue was suspended in water, filtered off and 
washed with 10 % HCl, 10 % NaHCO3 and water. Re-
crystallization from chloroform-diethyl ether give 1.62 
g (30.4 %) of pale brown powder, m.p. > 250 °C; IR 
(νmax / cm–1): 3345, 1487, 1326, 1092, 747, 497; 1H 
NMR (DMSO-d6) δ /ppm: 9.72 (s, 2H, CONH), 9.32 (br 
s, 4H, NH), 9.08 (br s, 4H, NH), 7.94 (d, 4H, J = 8.90 
Hz, ArH), 7.88 (d, 4H, J = 9.05 Hz, ArH) 4.59 (s, 4H, 
OCH2CH2O); 13C NMR (DMSO-d6) δ /ppm: 165.2, 
159.2, 143.3, 141.9, 129.7, 123.3, 120.3, 116.6, 65.9; 
HRMS: calcd. for C22H21N6O4S (M+H)+, 465.1345; 
found: 465.1332; Anal. Calcd. mass fractions of ele-
ments, w / %, for C22H20N6O4S × 2HCl × 4H2O (Mr = 
609.49): C 43.35, H 4.96, N 13.79, S 5.26; found: C 
43.39, H 4.72, N 13.56, S 5.29. 
 
2,5-Bis[N-(4-N'-isopropylamidinophenyl)carboxamide]- 
3,4-ethylenedioxythiophene Dihydrochloride (5b) 
Compound 4b (1.40 g, 6.6 mmol) was added to a stirred 
suspension of 3,4-ethylenedioxythiophene-2,5-dicarbo-
nyl chloride (2) (0.94 g, 3.5 mmol) in dry chloroform 
(30 mL) and the mixture was stirred for 2 days at room 
temperature under nitrogen atmosphere. The solvent 
was removed under reduce pressure, and the residue 
was suspended in water and precipitated with acetone to 
yield 0.51 g (23.3 %) of white powder, m.p. > 250 °C, 
IR (νmax / cm–1): 3606, 3028, 1519, 1089, 597; 1H NMR 
(DMSO-d6) δ /ppm: 9.66 (s, 2H, CONH), 9.49+9.46 
(s+s, 2H, NH), 9.32 (br s, 2H, NH), 8.92 (br s, 2H, 
NH), 7.92 (d, 4H, J = 8.64 Hz, ArH), 7.75 (d, 4H, J = 
8.77 Hz, ArH), 4.59 (s, 4H, OCH2CH2O), 4.02 (m, 2H, 
CH), 1.28 (d, 12H, J = 6.33 Hz, CH3); 13C NMR 
(DMSO-d6) δ /ppm: 161.3, 158.6, 142.3, 141.3, 129.2, 
124.2, 119.8, 116.3, 65.5, 45.0, 21.2; HRMS: calcd. for 
C28H33N6O4S (M+H)+, 549.2284; found: 549.2268. 
Anal. Calcd. mass fractions of elements, w / %, for 
C28H32N6O4S × 2HCl (Mr = 621.59): C 54.10, H 5.51, N 
13.52, S 5.16; found: C 54.10, H 5.72, N 13.31, S 4.97. 
 
2,5-Bis[N-(4-N'-isobutylamidinophenyl)carboxamide]-
3,4-ethylenedioxythiophene Dihydrochloride (5c) 
To a suspension of dicarbonyl chloride (2) (0.54 g, 2.0 
mmol) in dry chloroform (120 mL), compound 4c (0.98 
g, 4.3 mmol) was added and the mixture was stirred for 
3 days at room temperature under nitrogen atmosphere. 
The solvent was removed under reduced pressure, and 
the residue was suspended in water and precipitated 
with acetone to yield 0.23 g (17.2 %) of white powder; 
m.p. > 250 °C, IR (νmax / cm–1): 3026, 1662, 1517, 1321, 
1244, 1095, 813, 649; 1H NMR (DMSO-d6) δ /ppm: 
9.67 (s, 4H, NH), 9.35 (s, 2H, NH), 8.94 (s, 2H, NH), 
7.93 (d, 4H, J = 8.77 Hz, ArH), 7.77 (d, 4H, J = 8.74 
Hz, ArH), 4.59 (s, 4H, OCH2CH2O), 3.22 (d, 4H, J = 
6.98 Hz, CH2) 2.00 (m, 1H, J = 6.78 Hz, CH), 0.98 (d, 
12H, J = 6.66 Hz, CH3); 13C NMR (DMSO-d6) δ /ppm: 
162, 141, 136, 129, 126, 125, 114, 65, 49, 27, 19; 
HRMS: calcd. for C30H37N6O4S (M+H)+, 577.2597; 
found: 577.2582. Anal. Calcd. mass fractions of ele-
ments, w / %, for C30H36N6O4S × 2HCl × 2.5H2O (Mr = 
694.68): C 51.87, H 6.24, N 12.10, S 4.62; found: C 
51.98, H 5.88, N 11.81, S 4.55. 
 
2,5-Bis[N-(4-N'-cyclopentylamidinophenyl)carboxami- 
de]-3,4-ethylenedioxythiophene Dihydrochloride (5d) 
To a suspension of dicarbonyl chloride (2) (0.25 g, 0.9 
mmol) in dry chloroform (70 mL), compound 4d (0.39 
g, 1.6 mmol) was added and the mixture was stirred 
under reflux for 3 days under nitrogen atmosphere.  
The solvent was removed under reduce pressure, and  
the residue was suspended in water and precipitated  
with acetone to yield 0.22 g (38.6 %) of white powder;  
m.p. > 250 °C, IR (νmax / cm–1): 3004, 1522, 1320, 1097, 
743, 646; 1H NMR (DMSO-d6) δ /ppm: 9.68 (s, 2H, 
CO-NH), 9.62+9.59 ( br s+s, 2H, NH), 9.39 (br s, 2H, 
NH), 8.97 (br s, 2H, NH) 7.92 (d, 4H, J = 8.83 Hz, 
ArH), 7.77 (d, 4H, J = 8.78 Hz, ArH), 4.59 (s, 4H, 
OCH2CH2O), 4.12 (m, 2H, CH) 2.05 (m, 4H, CH2), 
1.75–1.57 (m, 12H, CH2); 13C NMR (DMSO-d6) δ /ppm: 
161.9, 158.6, 142.2, 141.4, 129.3, 124.1, 119.7, 116.2, 
65.4, 54.1, 31.4, 23.6; HRMS: calcd. for C32H37N6O4S 
(M+H)+, 601.2597; found: 601.2586. Anal. Calcd. mass 
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fractions of elements, w / %, for C32H36N6O4S × 2HCl × 
5H2O (Mr = 763.74): C 50.33, H 6.33, N 11.00, S 4.20; 
found: C 50.55, H 6.15, N 10.79, S 4.52. 
 
2,5-Bis[N-(4-(2-imidazolinyl)phenyl)carboxamide]-3,4-
ethylenedioxythiophene Dihydrochloride (5e) 
To a suspension of dicarbonyl chloride (2) (0.44 g, 1.7 
mmol) in dry chloroform (120 mL), compound 4e (0.72 
g, 3.7 mmol) was added and the mixture was stirred 
under reflux for 2 days under nitrogen atmosphere. The 
solvent was removed under reduced pressure, and the 
residue was suspended in water and precipitated with 
acetone to yield 0.27 g (25 %) of pale brown powder; 
m.p. > 250 °C, IR (νmax / cm–1): 3360, 1606, 1527, 1380, 
1087, 660, 595; 1H NMR (DMSO-d6) δ /ppm: 10.55 (s, 
4H, NH), 9.77 (s, 2H, NH), 8.03 (d, 4H, J = 9.02 Hz, 
ArH 7.98 (d, 4H, J = 9.07 Hz, ArH), 4.59 (s, 4H, 
OCH2CH2O), 4.00 (s, 8H, CH2); 13C NMR (DMSO-d6) 
δ /ppm: 164.7, 159.2, 143.8, 142.0, 130.1, 120.5, 117.6, 
116.7, 65.9, 44.9. HRMS: calcd. for C26H25N6O4S 
(M+H)+, 517.1658; found: 517.1641. Anal. Calcd. mass 
fractions of elements, w / %, for C26H24N6O4S × 2HCl × 
4H2O (Mr = 661.56): C 47.20, H 5.18, N 12.70, S 4.85; 
found: C 47.07, H 4.93, N 12.44, S 4.90. 
 
2,5-Bis[N-(4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl)- 
carboxamide]-3,4-ethylenedioxythiophene 
Dihydrochloride (5f) 
To a suspension of dicarbonyl chloride (2) (0.0.39 g, 1.5 
mmol) in dry chloroform (100 mL), compound 4f (0.63 
g, 3 mmol) was added and the mixture was stirred at  
50 °C for 4 days under nitrogen atmosphere. The sol-
vent was removed under reduce pressure, and the resi-
due was suspended in water and precipitated with ace-
tone to yield 0.16 g (17.4 %) of white powder; m.p. > 
250 °C, IR (νmax / cm–1): 3253, 1641, 1535, 1307, 
1157,1093, 847, 671; 1H NMR (DMSO-d6) δ /ppm: 9.93 
(s, 4H, NH), 9.67 (s, 2H, NH), 7.94 (d, 4H, J = 8.7 Hz, 
ArH), 7.76 (d, 4H, J = 8.7 Hz, ArH), 4.58 (s, 4H, 
OCH2CH2O), 3.49 (t, 8H, J = 5.22 Hz, CH2), 1.98 (m, 
4H, J = 4.95 Hz, CH2); 13C NMR (DMSO-d6) δ /ppm: 
159.1, 158.9, 142.7, 141.9, 129.0, 123.9, 120.4, 116.7, 
65.9, 18.3; HRMS: calcd. for C28H29N6O4S (M+H)+, 
545.1971; found: 545.1935. Anal. Calcd. mass fractions of 
elements, w / %, for C28H28N6O4S × 2HCl × 4H2O (Mr = 
689.62): C 48.77, H 5.55, N 12.19, S 4.65; found: C 
49.15, H 5.82, N 11.90, S 4.72. 
 
2,5-Bis[N-(3-amidinophenylcarboxamide)]-3,4-ethylene-
dioxythiophene Dihydrochloride (5g) 
Suspension of 3,4-ethylenedioxythiophene-2,5-dicarbo-
nyl chloride (2) (0.47 g, 1.77 mmol) and compound 4g 
(0.61 g, 3.56 mmol) in dry chloroform (100 mL) was 
stirred under reflux for 2 days under nitrogen atmos-
phere. The solvent was removed under reduce pressure 
and the residue was suspended in water and precipitated 
with acetone to yield 0.69 g (72.6 %) of pale brown 
powder; m.p. > 250 °C, IR (νmax / cm–1): 2971, 1668, 
1517, 1319, 1094, 820, 644; 1H NMR (DMSO-d6) 
δ /ppm: 9.58 (s, 2H, CONH), 9.41 (s, 4H, NH), 9.13 (s, 
4H, NH), 8.22 (s, 2H, ArH), 8.02 (d, 2H, J = 8.30 Hz, 
ArH), 7.64 (t, 2H, J = 7.92 Hz, ArH), 7.56 (d, 2H,  
J = 7.89 Hz, ArH), 4.61 (s, 4H, OCH2CH2O); 13C NMR 
(DMSO-d6) δ /ppm: 166.2, 159.1, 141.7, 138.8, 130.1, 
129.3, 125.7, 124.2, 120.2, 116.5, 65.9. HRMS: calcd. 
for C22H21N6O4S (M+H)+, 465.1345; found: 465.1348. 
Anal. Calcd. mass fractions of elements, w / %, for 
C22H20N6O4S × 2HCl × 2.5H2O (Mr = 582.46): C 45.37, 
H 4.67, N 14.43, S 5.51; found: C 45.04, H 4.55, N 
13.89, S 5.58. 
 
2,5-Bis[N-(3-(2-imidazolinyl)phenyl)carboxamide]-3,4-
ethylenedioxythiophene Dihydrochloride (5h) 
To a suspension of dicarbonyl chloride (2) (0.45 g, 1.7 
mmol) in dry chloroform (100 mL), compound 4h (0.68 
g, 3.4 mmol) was added and the mixture was stirred 
under reflux for 7 days under nitrogen atmosphere. The 
solvent was removed under reduced pressure, and the 
residue was suspended in water and precipitated with 
acetone to yield 0.14 g (14,5 %) of pale brown powder; 
m.p. > 250 °C, IR (νmax / cm–1): 3346, 3078, 2958, 1663, 
1425, 1251, 1160, 1035, 932, 877, 842, 801, 749, 644, 
587, 541, 467 ; 1H NMR (DMSO-d6) δ /ppm: 10.67 (s, 
4H, NH), 9.58 (s, 2H, NH), 8.40 (s, 2H, ArH), 7.98 (d, 
2H, J = 8.35 Hz, ArH), 7.71 (d, 2H, J = 7.80 Hz, ArH), 
7.66 (t, 2H, J1 = 7.97 Hz, ArH), 4.60 (s, 4H, 
OCH2CH2O), 4.01 (s, 8H, CH2); 13C NMR (DMSO-d6) 
δ /ppm: 164.7, 158.5, 141.3, 138.5, 129.9, 126.0, 124.2, 
122.8, 120.4, 116.0, 65.5, 44.3; HRMS: calcd. for 
C26H25N6O4S (M+H)+, 517.1658; found: 517.1631. 
Anal. Calcd. mass fractions of elements, w / %, for 
C26H24N6O4S × 2HCl × 5H2O (Mr = 679.58): C 45.95, H 
5.34, N 12.37, S 4.72; found: C 46.12, H 5.50, N 12.33, 
S 4.53. 
 
Mercurimetric Chloride Determination 
General Method 
A solution of 5a (1.5 mg in 5 ml of water) was prepared. 
0.2 mL of nitric acid (c = 4.99  10–2 mol dm–3) and 
0.04 mL of diphenylcarbazone ethanol solution (c = 
4.16  10–3 mol dm–3) were added and the mixture was 
titrated with standard Hg(NO3)2 (c = 5.11  10–3 mol 
dm–3). Intensive purple coloration (complex of 
diphenylcarbazone with mercuric ions) occurred at the 
equivalence point where the amount of Hg2+ corre-
sponds to 0.5 n(Cl−). 
 
Potentiometric Measurements 
General Method 
A solution of 5a for pH measurement was prepared 
using redistilled water. The electrode used for pH meas-
urements was a combined glass electrode, Metrohm LL 
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Micro glass electrode 6.0234.100. with a Methrohm 827 
pH meter. The temperature was kept constant at (25.0  
0.1) °C during pH measurements. Three standard buffer 
solutions (pH = 3, 6 and 9) were used for electrode 
calibration. 
 
Spectroscopy  
Electronic absorption spectra were recorded on a Varian 
Cary 100 Bio and PerkinElmer Lambda 25 spectrome-
ter, fluorescence emission spectra were recorded on a 
Varian Eclipse fluorimeter, and CD spectra on a Jasco 
J815, in all cases using quartz cuvettes (1 cm). Meas-
urements were performed in an aqueous buffer solution 
(pH = 7; sodium cacodylate buffer, Ic = 0.05 mol dm–3). 
Under the experimental conditions used, the absorbance 
and fluorescence intensities of the studied compounds 
were proportional to their concentration. Polynucleo-
tides were purchased from Sigma and Aldrich and were 
dissolved in sodium cacodylate buffer (Ic = 0.05 mol 
dm–3, pH = 7). Calf thymus DNA (ct-DNA) was addi-
tionally sonicated and filtered through a 0.45 µm filter. 
Their concentration was determined spectroscopically 
as the concentration of phosphates.30 Spectroscopic 
titrations were performed by adding portions of polynu-
cleotide solution into the solution of the studied com-
pound. Obtained data were corrected for dilution.  
DNA binding experiments were performed at 
(25.0 ± 0.2) °C. The UV-Vis titration of diamidines  
5a–h was performed in a buffer (sodium cacodylate 
buffer, Ic = 0.05 mol dm–3, pH = 7) medium using a 
fixed complex concentration, to which increments of the  
ct-DNA stock solutions (0.0–3.5 × 10–4 mol dm–3) were 
added. The resulting solutions were incubated for 10 
min before the absorption spectra were recorded.  
DNA-melting experiments were carried out by 
monitoring the absorbance of ct-DNA and poly A–poly 
U at λ = 260 nm at varying temperature in the absence 
and presence of diamidines 5a–h, at r = 0.1, 0.2, 0.3 and 
0.5 compound to polynucleotide ratio with a ramp rate 
of 0.5 °C min–1 in the buffer (pH = 7) using a Peltier 
system attached to the UV-Vis spectrophotometer. Ab-
sorbance of the ligands was subtracted from every 
curve, and the absorbance scale was normalized. Melt-
ing temperature (Tm) values are the midpoints of transi-
tion curves, determined from the maximum of the first 
derivative and checked graphically by the tangent meth-
od.23 Tm values were calculated subtracting Tm of the 
free nucleic acid from Tm of the complex. Every Tm 
value here reported was the average of at least two 
measurements, the error in Tm was  0.5 °C. 
Ethidium bromide (EB) displacement assay:  
to polynucleotide solution (c = 5  10–5 mol dm–3),  
ethidium bromide (c = 5  10–6 mol dm–3) was added  
(r ([EB] / [polynucleotide]) = 0.1), and quenching of  
the EB /polynucleotide complex fluorescence emission  
(ex = 520 nm, em = 601 nm) was monitored as a func-
tion of c(EB) /c(compound). The given IC50 values 
represent the ratio c(EB) / c(compound) = [Int(EB /  
polynucleotide) – Int(EBfree)] / 2, where Int(EB / poly- 
nucleotide) is the fluorescence intensity of the EB / poly- 
nucleotide complex and Int(EBfree) is the fluorescence 
intensity of the free ethidium bromide before polynu-
cleotide was added. The apparent binding constants 
were calculated from: KEtBr × [EtBr] = Kapp × [drug], 
where [drug] = concentration of the tested compound at 
a 50 % reduction of fluorescence. The binding constant 
of ethidium bromide to calf thymus DNA under compa-
rable conditions is 1.0 × 106 mol–1 dm3.30 
 
Cell Culturing and MTT Test  
Five tumour cell lines, colorectal adenocarcinomas 
(CaCo2, HT29), larynx carcinoma (HEp2), cervix ade-
nocarcinoma (HeLa), pancreatic adenocarcinoma (MI-
APaCa2) and Madine-Darby canine kidney (MDCKI) 
normal cells were grown in DME medium (Gibco, EU). 
The bronchioalveolar carcinoma (NCI H358) and gastric 
adenocarcinoma (AGS) tumour cell lines were grown in 
RPMI 1640 medium (Gibco, EU). Both media were sup-
plemented with 10 % heat-inactivated foetal bovine se-
rum-FBS (Gibco, EU), 2 × 10–3 mol dm–3 glutamine 
(Gibco, EU), 1 × 10–3 mol dm–3 sodium pyruvate (Gibco, 
EU), 1 × 10–2 mol dm–3 HEPES (Sigma-Aldrich, USA) 
and 100 U / 0.1 mg antibiotic /antimycotic (Gibco, EU). 
Cells were grown at t = 37 °C, with 5 % CO2 gas 
in humidified CO2 incubator (ShelLab, Sheldon Mfg. 
Inc., USA). The trypan blue dye exclusion method was 
used to assess cell viability. Tested compounds were 
dissolved in high-purity water as a 1 × 10–2 mol dm–3 
stock solution. Working dilutions were prepared in a 
concentration range 10–3–10–6 mol dm–3. 
For the MTT31 test, cells were seeded in 96 micro-
well flat bottom plates (Greiner, Austria) at 2 × 104 
cells /mL. After 72 hours of incubation with the tested 
compounds MTT (Merck, Germany) was added. DMSO 
(Merck, Germany) was used to dissolve the MTT-
formazane crystals formed. Absorbance was measured 
at 570 nm on Stat fax 2100 plate reader (Awareness 
Technology Inc., USA). 
All experiments were performed three times in 
triplicates. The IC50 value, defined as the concentration 
of compound achieving 50 % of cell growth inhibition, 
was calculated and used to compare cytotoxicity among 
the compounds. 
 
RESULTS AND DISCUSSION 
Chemistry 
The target amido-amidines 5a–h were synthesized ac-
cording to the procedure outlined in Scheme 1 by the 
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condensation reaction of 3,4-ethylenedioxythiophene-
2,5-dicarbonyl chloride (2) and corresponding 3- or 4-
aminobenzamidines 4a–h. Dicarbonyl chloride 2 was 
prepared in good yield (89 %) by reaction of 3,4-
ethylenedioxythiophene-2,5-dicarboxylic acid (1) with 
thionyl chloride and DMF in dry benzene.23 3- or 4-
aminobenzamidines 4a–h were purchased (4a, 4e, 4f 
and 4g) or synthesized from commercially available 
aminobenzonitrile by means of the Pinner reaction (4b, 
4c, 4d and 4h). 
The number and nature of positively charged 
groups in small molecules that bind in the minor groove 
of DNA play an important role in complex formation.32 
In general, these molecules should have a minimum two 
cationic groups to show significant binding and biologi-
cal activity. Due to the high pK values of the amine 
moieties and low solubility of the compounds, the num-
ber of protons per molecule present in compounds 5a–h 
and the corresponding pK values could not be deter-
mined by standard potentiometric pH titration. There-
fore, the concentration of the chloride anion in solutions 
of studied compounds was determined by mercurimetric 
titration using diphenylcarbazone as indicator.33 In all 
cases, the Cl− concentration was two times higher than 
the concentration of the compound, which confirms the 
presumption that all investigated compounds were iso-
lated as dihydrochlorides. The measured pH values of 
5a and 5b solutions (c = 5 × 10–4 mol dm–3) were 8.454 
and 8.357, respectively, suggesting that no dissociation 
occurred after 5a and 5b were dissolved in water. These 
findings indicate that pK values of the investigated 
compounds are quite high (> 10) which is in agreement 
with previous studies.34 It can be therefore concluded 
that under physiological conditions (pH = 7) all pre-
pared compounds exist as dications. 
 
UV-Vis and Fluorescence Spectroscopic Characteris-
tics of Compounds 5a–h 
Based on the position of terminal amidine moieties, 
compounds 5a–h are divided into two groups: para 
derivatives (5a–f, Scheme 1) and meta derivatives (5g 
and 5h, Scheme 1). Since DNA binding studies are 
conducted by spectrophotometric methods, the spectro-
scopic behaviour of aqueous solutions of investigates 
compounds 5a–h was studied by UV-Vis (Figure 2, 
Table 1) and fluorescence spectrophotometry (Figure 3) 
performed at room temperature. 
Linear dependence of UV-Vis spectra on the  
concentration of all studied compounds in the range c 
(5a–h) = 1.97 – 4.92 × 10–5 mol dm–3 as well as negligi-
ble temperature dependent changes (25–90 °C) and 
excellent reproducibility upon cooling to 25 °C indicat-
ed the absence of intermolecular interactions. Aqueous 
solutions of all studied compounds were stable over 
several weeks. 
UV-Vis spectroscopic properties of the synthe-
sized compounds are strongly dependent on the nature 
and position of the amidine group. UV-Vis spectra of 
para derivatives 5a–f showed two absorption maxima, 
one in the 246–261 nm range, and the other, more in-
tense, in the 327–335 nm range (Figure 2, Table 1). The 
meta derivatives 5g and 5h showed only one absorption 
maximum at λ = 318 nm, of lower molar extinction 
 
Scheme 1. Reagents: (i) SOCl2, DMF, benzene; (ii) 1. HCl /CH3OH, 2. R–NH2, CH3OH; (iii) CHCl3. 
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values (ε) and blue shifted in comparison to their para 
analogues. These differences resulted from the position 
of amidine groups within molecules. 
Within para derivatives, alkylation of parent com-
pound 5a or introduction of 1,4,5,6-tetrahydropyri-
midine as amidine moiety resulted in a decrease of mo-
lar extinction values (ε) while retaining the position of 
absorption maxima. On the other hand, introduction of 
imidazoline, a cyclic amidine moiety, resulted in an 
increase of molar extinction values (ε) along with a red 
shift of maxima by about 10 nm. The same result was 
also obtained in meta derivatives. 
Fluorescence emission of compounds 5a–f (Sup-
plement: Figure S1) was proportional to their concentra-
tion up to 3 × 10–6 mol dm–3, the relative fluorescence 
intensity varying with compound structure. 
 
Interactions with Double Stranded (ds-) DNA and 
RNA 
Low fluorescence emission of all studied compounds even 
at 5 × 10–6 mol dm–3 concentrations and maximum instru-
ment sensitivity hampered the application of fluorimetric 
titrations in studies of interactions with DNA/RNA. 
 
UV-Vis Titrations with Polynucleotides 
UV-Vis spectroscopy is an effective tool to study the 
interactions of small molecules with polynucleotides. 
Here, UV-Vis titrations were performed in a buffered 
medium (sodium cacodylate buffer, Ic = 0.05 mol dm–3, 
pH = 7) at room temperature. Addition of ct-DNA to a 
solution of compounds 5a–h resulted in a pronounced 
hypochromic effect of their absorption spectra > 300 nm, 
while no significant shift of maxima was observed (Fig-
ure 3, Table 2, Supplement: Figure S2). 
Addition of ct-DNA induced changes in UV-Vis 
spectra of all tested compounds up to the ratio  
r[compd]/[ctDNA] = 0.2–0.5, while further additions of the 
Figure 2. UV-Vis spectra of 5a–h at c = 1.97–4.92 × 10–5
mol dm–3. 
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Table 1. Electronic absorption maxima and corresponding 
molar extinction coefficients of studied compounds in water 
Compound max / nm 103 / dm3 mol–1 cm–1
5a 252 330 
16.9 
57.6 
5b 246 328 
16.9 
47.6 
5c 246 327 
13.8 
40.5 
5d 246 329 
20.0 
53.6 
5e 261 335 
22.1 
63.2 
5f 246 328 
19.8 
49.3 
5g 318 29.1 
5h 318 33.3 
 
Figure 3. Changes in UV-Vis spectrum of 5a (c = 1.08  10–5 mol dm–3) upon titration with ct-DNA (a) and poly A–poly U (b);
at pH = 7, Na cacodylate buffer, Ic = 0.05 mol dm–3. 
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mentioned polynucleotide did not produce any addition-
al spectral changes, suggesting that at the mentioned ratio 
r, tested compounds were completely bound to ct-DNA. 
Changes observed in the UV-Vis spectra of com-
pounds 5a–h in ct-DNA titrations, along with a clear 
deviation from the isosbestic points > 300 nm, suggest-
ed formation of at least two different types of complex-
es with ct-DNA.  
Addition of ds-RNA (poly A–poly U) to diamidines 
5a–h induced smaller changes in the UV-Vis spectra of 
tested compounds in comparison with DNA titrations 
(Figure 3b, Table 2).  
 
Thermal Melting Experiments 
Changes in the melting point (Tm) of ct-DNA and ds-RNA 
upon the addition of compounds 5a–h were measured in 
the range of r[compound]/[polynucleotide] = 0–0.5. While all stu-
died compounds had a considerable stabilisation impact 
on the thermal denaturation of ct-DNA, their addition 
did not stabilize ds-RNA (poly A–poly U) (Table 3). 
Circular Dichroism (CD) Experiments 
Thus far, non-covalent interactions at temperature of  
25 C were studied by monitoring the spectroscopic 
properties of studied compounds upon addition of poly-
nucleotides. To get an insight into the changes of poly-
nucleotide properties induced by small molecule bind-
ing, we have chosen CD spectroscopy as a highly sensi-
tive method for conformational changes in the second-
ary structure of polynucleotides.35 In addition, achiral 
small molecules can eventually acquire an induced CD 
spectrum (ICD) upon binding to polynucleotides, which 
could give useful information about the modes of inter-
action.35–39 Amidine derivatives 5a–h are not chiral and 
therefore do not possess an intrinsic CD spectrum, but 
when added to ct-DNA, they acquire induced CD (ICD) 
bands > 300 nm (Supplement: Figure S3), agreeing well 
with the corresponding UV spectra (Figure 3).  
Addition of most of the studied compounds to ds-
RNA (poly A–poly U) resulted in similar, bisignate ICD 
bands > 300 nm, characterised by an isoelliptic point 
(only one type of complex) and negative/positive band 
distribution taken from shorter wavelengths. Such 
bisignate ICD bands could be attributed to the dye-
dimer formation,35 most likely within the ds-RNA major 
groove since the shallow and very wide RNA minor 
groove is not convenient for the binding of small mole-
cules. Due to the large size of the binding site, dimeric 
dye aggregates are easily accommodated and therefore 
the secondary structure of the double helix is not signif-
icantly disturbed, showing only small changes in CD 
bands of ds-RNA (< 300 nm). The only exception was 
observed for 5f, characterized by the largest rigid 
amidine substituent in the series, whereby the absence 
of an isoelliptic point and un-symmetric ICD band > 
300 nm of the reversed order (weak positive/strong 
negative band taken from shorter wavelengths) suggest-
ed the presence of several different forms of dye aggre-
gates along the ds-RNA.  
Table 3. The ΔTm / °C(a) values of studied ct-DNA and poly A–poly U upon addition of different ratios r(b) of tested compounds at 
pH = 7.0 (buffer sodium cacodylate, Ic = 0.05 mol dm–3) 
polynucleotide r(b) 
ΔTm / °C(a) 
5a 5b 5c 5d 5e 5f 5g 5h 
ct-DNA 
0.1 1.3 1.6 2.1 2.5 1.2 1.4 0.8 1.8 
0.2 3.3 2.9 3.1 4.7 2.3 4 1.9 2.5 
0.3 6 3.8 3.4 7.0 – 4.5 2.7 3.4 
0.5 – 6.4 9.2 – – 8.9 4.4 6.5 
          
poly A–poly U 
0.1 0.1 0.4 0.3 0.3 0.2 0.2 0.3 0.3 
0.2 0.1 0.5 0.5 0.8 0.9 – 0.5 0.6 
0.3 – 0.5 0.5 – – – 0.6 – 
(a) Error in Tm:  0.5 °C. 
(b) r = [compound] / [polynucleotide]. 
Table 2. Changes in the UV-Vis spectra of 5a–h upon titration 
with ct-DNA and poly A–poly U (pH = 7, Na cacodylate buffer, 
Ic = 0.05 mol dm–3) 
Compound ct-DNA H / % (a) 
poly A–poly U 
H / % (a) λmax / nm 
5a 36 15 330 
5b 43 22 328 
5c 25 17 327 
5d 31 11 329 
5e 44 37 335 
5f 23 21 328 
5g (b) (c) 318 
5h 11 7 318 
(a) Hypochromic effect; H = ((Acompd. – Acomplex) / Acompd.) · 100. 
(b) Absorbance changes in opposite direction (Figure 3): A decre-
ases for r = 4–0.88, followed by increase of A for r > 0.88. 
(c) Absorbance changes in opposite direction (Figure 3): A decre-
ases for r = 4–0.66, followed by increase of A for r > 0.66. 
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Changes in the CD spectrum of ct-DNA were de-
pendent on the size and flexibility of amidine substitu-
ents attached to 5a–h. Addition of 5a, 5b, 5g and 5h 
characterised by small acyclic amidines resulted in a 
strong negative ICD band > 300 nm, combined with 
various changes in CD spectra < 300 nm. It should  
be noted that at 300 nm it is not possible to distinguish 
between the possible ICD bands of dye and changes in 
the CD spectrum of ct-DNA caused by small molecule 
distorting the double helical structure. At variance to 5a, 
5b, 5g and 5h, the largest acyclic (5c and 5d) and all 
cyclic para amidine (5e and 5f) derivatives yielded 
bisignate ICD bands > 300 nm, characterised by an 
isoelliptic point (only one type of dye-DNA complex) 
and negative/positive band distribution taken from 
shorter wavelengths. Such bisignate ICD bands could be 
attributed to the dye-dimer formation,35 most likely 
within the ct-DNA minor groove.  
The similarity of bisignate ICD bands > 300 nm 
observed for 5d–f/ct-DNA complexes and 5a–e, 5g and 
5h/ds-RNA complexes suggests a similar type of dimer-
ic-dye form. Obviously, the fine interplay between the 
amidine substituent size and the DNA/RNA groove 
steric and non-covalent interaction properties controls 
the dye-dimer formation and consequently the charac-
teristic ICD profile. 
 
Ethidium Bromide Displacement Assay 
Displacement of EB pre-bound to ds-DNA by succes-
sive additions of the studied compounds provides an 
indirect method of measuring the binding affinity of 
compounds by qualitative comparison of binding affini-
ties within a series of compounds with similar struc-
ture.40,41 The extent of quenching of the fluorescence of 
EB bound to DNA would reflect the extent of DNA 
binding of the studied molecule, thus allowing a rough 
estimation of the affinity of the studied molecule toward 
ds-DNA.42 
The obtained IC50 values (Figure 4) suggest that 
affinity of 5a, 5c, 5e, 5g and 5h toward ct-DNA is com-
parable to the affinity of EB, while in the case of com-
pounds 5b, 5d and 5f, IC50 of the fluorescence of 
ethidium bromide-ct-DNA complexes was not reached. 
Table 4 presents the DNA association constants (Kapp) 
of compounds 5a, 5c, 5e, 5g and 5h in comparison with 
ethidium bromide. 
 
Antiproliferative Capacity of Compounds 5a–h 
New compounds 5a–h may be viewed as amide ana-
logues of compounds I and II showed in Figure 1. After 
evaluating the influence of expansion of the central part, 
by introduction of an amide bond (in the structure of 
compounds I) or replacement of the rigid part 
(benzimidazole in compounds II) with the flexible one 
(benzamide), on DNA binding mode by UV-Vis, fluo-
rescence, CD and UV-melting methods, cytotoxic ef-
fects on normal and tumour cells were checked.  
A number of recent studies conducted on the tu-
mour cell lines of different origin showed that some 
derivatives of benzimidazole, diarylamidine, and bis-
benzimidazoles are cytotoxic against tumour cells de-
rived from solid organ tumours,22,23,43,44 as well as from 
haematological tumours.45 The newly synthesized com-
pounds were tested for their antiproliferative effects on 
normal cells (MDCKI) and seven human tumour cell 
lines of different histological origin (HT-29, AGS, 
MIAPaCa2, CaCo2, HEp2, HeLa and NCI H358). The 
results are presented in Table 5 as IC50 values, the con-
centration achieving 50 % of cell growth inhibition. 
Doxorubicin was used as a control. Obtained data show 
that investigated compounds differentially influenced 
tumour cell growth, depending on the cell line as well as 
on the dose applied. Compounds 5a, 5g and 5h in con-
centration of 10–4 mol dm–3 showed strong inhibitory 
potential on normal cells and all tumour cell lines (IC50 
values ranging from 14–37 × 10–6 mol dm–3 for 5a, 
from 15–68 × 10–6 mol dm–3 for 5g, and 16–76 × 10–6 
mol dm–3 for 5h). An exception was the weak inhibitory 
Table 4. Association constants of investigated compounds with 
ct-DNA 
 10–5 × Kapp / dm3 mol–1 
Compound    EB(a) 5a 5c 5e 5g 5h 
 10.0 2.18 0.60 1.41 0.98 1.82 
(a) Ref. 30. 
Figure 4. Ethidium bromide (EB) displacement assay: to ct-
DNA solution (c = 5  10–5 mol dm–3) ethidium bromide (c =
5  10–6 mol dm–3) was added (r ([EB]/[ct-DNA]) = 0.1), and
quenching of the EB/DNA complex fluorescence emission
(ex = 520 nm, em = 601 nm) was monitored as function of
c(EB) /c(compound). The given IC50 values present the ratio
c(EB) /c(compound) = [Int(EB/DNA)–Int(EBfree)] /2, where
Int(EB/DNA) is fluorescence intensity of EB/DNA complex
and Int(EBfree) is fluorescence intensity of the free ethidium
bromide before DNA is added.  
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effect of compound 5a on the AGS cell line, which 
could be explained by high multidrug resistance pheno-
type of AGS cells.46,47 Compounds 5b, 5c, 5d and 5f 
showed very weak activity on the proliferative capacity 
of the majority of tested cells lines. Although a rapid 
cellular uptake and nuclear accumulation of 
benzimidazole-based amidines in different cancer cells 
have been recently evidenced by fluorescence micros-
copy,48 the possibility cannot be excluded that the ob-
served difference in cytotoxicity of new compounds was 
a consequence of different cellular uptake. For that 
reason, the entry of compounds and intracellular distri-
bution will be investigated. 
 
CONCLUSION 
Interactions of amidine derivatives of EDOT such as 
those in Figure 1 with nucleic acids are of interest for 
two primary reasons: they have shown very significant 
anticancer activity that appears to be related to their 
ability to complex with DNA and they provide unique 
probes of the nucleic acid sequence depending molecu-
lar recognition.  
A series of eight diamidine derivatives of EDOT, 
namely, 2,5-bis[(amidinophenyl)carboxamide]-3,4-ethyle-
nedioxythiophene 5a–h with terminal amidine group in 
para- or meta- position (Scheme 1), was synthesized. 
Both, the position and nature of substituents were 
changed to determine their influence on the DNA bind-
ing mode and anticancer properties.  
Based on the position of terminal amidine groups 
two set of structural isomers with amidine substituents 
in para-para (5a–f) and meta-meta (5g and 5h) posi-
tions were studied. DNA binding studies revealed that 
the spectra of investigated compounds supported for-
mation of at least two different types of complexes with 
ct-DNA as a result of deviation from isosbestic points. 
Due to several binding modes of compounds 5a–h, it 
was not possible to calculate the binding constants. 
Thermal melting experiments have shown that all 
investigated compounds 5a–h interact with ct-DNA to 
stabilize the duplex structure. Tm measurement at r = 
0.1 revealed that alkylation of parent compound 5a 
resulted in an overall increase of Tm values, while 
substitution of the amidine moiety with cyclic ones, 
imidazoline or 1,4,5,6-tetrahydropyrimidine did not 
affect the values of Tm.  
ICD spectra of investigated compounds 5a–h with 
ct-DNA support binding of studied compounds within 
the DNA minor groove either as single molecules (small 
substituents on amidines, only one ICD band) or for 
compounds with larger amidine substituents as dimeric 
forms (bisignate ICD bands). The bisignate ICD bands 
observed upon addition of derivatives 5a–h to poly A–
poly U, could be attributed to dimerization of com-
pounds within the RNA major groove. Obviously, the 
fine interplay between the amidine substituent size and 
different steric and non-covalent interaction properties 
of the ds-DNA minor groove and ds-RNA major 
groove, respectively, control the dye-dimer formation 
and consequently characteristic ICD profile. Ethidium 
bromide displacement studies have shown that com-
pounds 5a, 5c, 5e, 5g and 5h efficiently compete with 
ethidium bromide in binding to ct-DNA (Kapp at IC50 
Table 4), at variance to 5b, 5d and 5f which needed 
much higher concentrations to displace EB from DNA. 
Obtained IC50 did not correlate with thermal melting 
experiments, whereby the compounds 5d and 5f show-
ing the highest stabilisation effects on ct-DNA, were the 
most inefficient in displacing ethidium bromide from 
DNA. This discrepancy could be attributed to the differ-
ent binding modes of studied compounds (DNA minor 
groove) and ethidium bromide (intercalation). 
The in vitro anticancer properties of the new com-
pounds depend on the tested compound, the cell line, as 
Table 5. Sensitivity of human tumour and normal cells to investigated compounds, expressed as IC50 /μmol dm–3 (a) 
Compound Normal cell line MDCKI 
Solid tumour cell lines 
HT29 AGS MIAPaCa2 CaCo2 HEp2 HeLa NCI H358 
5a 14 ± 5.1 37± 26.9 125 ± 33.1 22 ± 3.1 29 ± 9.8 22 ± 4.3 17 ± 1.7 27 ± 1.7 
5b 161 ± 6.5 172± 7.8 149 ± 32.2 154 ± 39.9 157 ± 38.6 123 ± 22.0 170 ± 13.9 147 ± 5.2 
5c 181 ± 5.05 154± 17.5 50 ± 7.0 102 ± 12.0 155 ± 14.4 156 ± 8.9 125 ± 4.9 98 ± 4.8 
5d 163 ± 12.2 114± 11.9 147 ± 1.2 123 ± 0.6 107 ± 22.3 99 ± 23.6 129 ± 4.1 138 ± 9.3 
5e 97 ± 0.1 139± 19.05 163 ± 2.9 195 ± 0.1 162 ± 5.7 155 ± 1.6 184 ± 9.0 136 ± 7.10 
5f 99 ± 13.8 86± 24.6 114 ± 29.7 87 ± 35.1 120 ± 8.6 106 ± 18.6 93 ± 4.9 73 ± 13.3 
5g 48 ± 42.5 35± 10.1 61 ± 47.2 15 ± 1.1 68 ± 14.9 66 ± 36.9 55 ± 22.8 38 ± 12.0 
5h 58 ± 10.0 76± 25.0 16 ± 2.95 30 ± 0.6 75 ± 23.0 28 ± 0.6 34 ± 3.25 29 ± 0.5 
Doxorubicin 0.3 ± 0.1 0.6± 0.32 0.2 ± 0.04 0.4 ± 0.05 0.7 ± 0.09 0.4 ± 0.06 4 ± 0.28 0.8 ± 0.13 
(a) IC50 - drug concentration that inhibited cell growth by 50 %. Data represents mean IC50 / μmol dm–3 values ± standard deviation 
(SD) of three independent experiments. Exponentially growing cells were treated with substances during 72 hrs period. Cyto-
toxicity was analysed using MTT survival assay. 
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well as on the dose applied. Since it cannot be excluded 
that the observed fractional antiproliferative potential of 
compounds was a consequence of a somewhat difficult 
access into cells, the entry of compounds and their in-
tracellular distribution will be investigated. 
Supplementary Materials. – Supporting informations to the 
paper are enclosed to the electronic version of the article. 
These data can be found on the website of Croatica Chemica 
Acta (http://public.carnet.hr/ccacaa).  
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Figure S1. Fluorescence emission spectra of 5a–h at c = 1.99 × 10–6 mol dm–3; at λexc. = 330 
(5a), 328 (5b, 5f), 335 (5e), 327 (5c), 329 (5d) nm. 
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Figure S2. Changes in UV-Vis spectrum of compounds 5a–h upon titration with ct-DNA 
(first column), UV-Vis spectra of compound and complex compound/ct-DNA at different 
ratios r = [compound]/[ct-DNA] (second column), spectroscopic changes at λmax as a function 
of ct-DNA concentration (third column) for a) 5a (c = 1.0  10–5 mol dm–3), λmax = 330 nm; b) 
5b (c = 2.5  10–6 mol dm–3), λmax = 328 nm; c) 5c (c = 3.6  10
–6
 mol dm
–3
), λmax = 327 nm; 
d) 5d (c = 1.0  10–5 mol dm–3), λmax = 329 nm; e) 5e (c = 3.6  10
–6
 mol dm
–3
), λmax = 335 
nm; f) 5f (c = 1.0  10–5 mol dm–3), λmax = 328 nm; g) 5g (c = 5.0  10
–6
 mol dm
–3
), λmax = 318 
nm; h) 5h (c = 3.6  10–6 mol dm–3), λmax = 318 nm. Experiments were done at pH 7 in Na 
cacodylate buffer, I = 0.05 mol dm
–3
. 
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Figure S3. CD titration of polynucleotides (c = 2.0  10–5 mol dm–3) with 5a–h at molar 
ratios r = [compound] / [polynucleotide] (pH 7, buffer sodium cacodylate, I = 0.05 mol dm
–3
). 
